Comparing VolitionRx (NYSE:VNRX) and OncoCyte (NASDAQ:OCX)

VolitionRx (NYSE:VNRX) and OncoCyte (NASDAQ:OCX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, institutional ownership, analyst recommendations and profitability.

Volatility & Risk

VolitionRx has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500. Comparatively, OncoCyte has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500.

Profitability

This table compares VolitionRx and OncoCyte’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
VolitionRx	-3,318.42%	N/A	-165.21%
OncoCyte	-3,558.46%	-149.88%	-45.79%

Insider & Institutional Ownership

8.1% of VolitionRx shares are owned by institutional investors. Comparatively, 55.3% of OncoCyte shares are owned by institutional investors. 12.8% of VolitionRx shares are owned by insiders. Comparatively, 1.9% of OncoCyte shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares VolitionRx and OncoCyte’s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VolitionRx	$770,000.00	86.12	-$35.32 million	($0.46)	-1.57
OncoCyte	$1.02 million	25.39	-$27.78 million	N/A	N/A

OncoCyte has higher revenue and earnings than VolitionRx.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for VolitionRx and OncoCyte, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VolitionRx	0	1	1	0	2.50
OncoCyte	0	2	2	0	2.50

VolitionRx presently has a consensus target price of $2.50, indicating a potential upside of 247.22%. OncoCyte has a consensus target price of $4.06, indicating a potential upside of 29.38%. Given VolitionRx’s higher probable upside, equities research analysts clearly believe VolitionRx is more favorable than OncoCyte.

Summary

VolitionRx beats OncoCyte on 6 of the 11 factors compared between the two stocks.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.

About OncoCyte

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.